actin monoclonal antibody Search Results


mouse monoclonal antibodies  (Cytoskeleton Inc)
95
Cytoskeleton Inc mouse monoclonal antibodies
Mouse Monoclonal Antibodies, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal antibodies/product/Cytoskeleton Inc
Average 95 stars, based on 1 article reviews
mouse monoclonal antibodies - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
β actin  (Bioss)
95
Bioss β actin
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
β Actin, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin/product/Bioss
Average 95 stars, based on 1 article reviews
β actin - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
anti actin mouse monoclonal antibody  (Valiant Co Ltd)
93
Valiant Co Ltd anti actin mouse monoclonal antibody
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Anti Actin Mouse Monoclonal Antibody, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti actin mouse monoclonal antibody/product/Valiant Co Ltd
Average 93 stars, based on 1 article reviews
anti actin mouse monoclonal antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
actin mp biomedicals 08637931  (Valiant Co Ltd)
86
Valiant Co Ltd actin mp biomedicals 08637931
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Actin Mp Biomedicals 08637931, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/actin mp biomedicals 08637931/product/Valiant Co Ltd
Average 86 stars, based on 1 article reviews
actin mp biomedicals 08637931 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
actin monoclonal antibody  (Proteintech)
96
Proteintech actin monoclonal antibody
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Actin Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/actin monoclonal antibody/product/Proteintech
Average 96 stars, based on 1 article reviews
actin monoclonal antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
mouse mab anti β actin  (Proteintech)
97
Proteintech mouse mab anti β actin
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Mouse Mab Anti β Actin, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mab anti β actin/product/Proteintech
Average 97 stars, based on 1 article reviews
mouse mab anti β actin - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
antibodies against β actin  (OriGene)
95
OriGene antibodies against β actin
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Antibodies Against β Actin, supplied by OriGene, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against β actin/product/OriGene
Average 95 stars, based on 1 article reviews
antibodies against β actin - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
mouse anti actin  (Valiant Co Ltd)
95
Valiant Co Ltd mouse anti actin
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Mouse Anti Actin, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti actin/product/Valiant Co Ltd
Average 95 stars, based on 1 article reviews
mouse anti actin - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
ta811000s  (OriGene)
94
OriGene ta811000s
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Ta811000s, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ta811000s/product/OriGene
Average 94 stars, based on 1 article reviews
ta811000s - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
anti β actin monoclonal antibody  (Boster Bio)
95
Boster Bio anti β actin monoclonal antibody
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Anti β Actin Monoclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti β actin monoclonal antibody/product/Boster Bio
Average 95 stars, based on 1 article reviews
anti β actin monoclonal antibody - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
mouse monoclonal β actin antibody  (Boster Bio)
91
Boster Bio mouse monoclonal β actin antibody
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Mouse Monoclonal β Actin Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal β actin antibody/product/Boster Bio
Average 91 stars, based on 1 article reviews
mouse monoclonal β actin antibody - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
anti β actin  (Boster Bio)
93
Boster Bio anti β actin
(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and <t>β-actin.</t> Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.
Anti β Actin, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti β actin/product/Boster Bio
Average 93 stars, based on 1 article reviews
anti β actin - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


(A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and β-actin. Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.

Journal: Cancer research

Article Title: Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance

doi: 10.1158/0008-5472.CAN-19-2549

Figure Lengend Snippet: (A, B) PC3 cells were co-transfected with AR plus IRF8 or AR plus vector control plasmid for 6h and treated with CHX (100 μg/mL) for the indicated time. Cell lysates were immunoblotted for AR, IRF8 and β-actin. Relative quantification was carried out for three biological replicates using β-actin as loading control. P-values were calculated using Student’s t test. ∗, p < 0.05; ∗∗, p < 0.01. (C) HEK293T cells were co-transfected with pIRF8, pAR or vector control for 48 h and incubated with CHX in the presence of proteasome inhibitor MG132 (10 μM), calpain inhibitors MG101 (10 μM), MG132 (0.1 μM), calpastatin (5 μM) or lysosomal inhibitor leupeptin (Leu, 50 μM) for 5 h, or DMSO as control. Cell lysates were analyzed for IRF-8 and β-actin expression. (D) Cells were cotransfected with the AR and control (pcDNA3.1) or IRF8 plasmids for 24 h, and treated with DMSO or MG132 (10 μM) for 5 h. Cell lysates were immunoblotted with the indicated antibodies. (E) Confocal microscopy for endogenous IRF8 and AR in LNCaP cells treated with DHT (10 nM) for 48 h. (F) Co-IP of IRF8 and AR in HEK293T cells co-transfected with pIRF8, pAR or vector control for 48 h. (G) Western blots were performed using indicated antibodies after IP of the full-length and truncated forms of AR from HEK293T WCL using the Flag antibody. (H) HEK293T cells were transfected with various combinations of pAR, pIRF8, and pFlag-Ub plasmids for 48 h. Cells were treated with MG132(10 μM) for 5 h, followed by nuclear and cytoplasmic protein lysate preparation and cytosolic protein were used for IP with an anti-AR antibody and IB with the indicated antibodies. (I) HEK293 cells were transfected with AR, IRF8, and WT, K48, or K63 ubiquitin (Ub) plasmids. Cells lysates were subjected to IP 48 h later with an anti-AR antibody followed by IB with an anti-HA antibody. (J) PC3 cells were first transfected with pcDNA3.1 or IRF8 for 12 h and then transfected again with HA-MDM2 or HA-MDM2 and AR for 48 h. The amount of plasmids was slightly adjusted to make the proteins expressed in similar level in different samples. Cell lysates were subjected to IP and followed by IB with the indicated antibodies.

Article Snippet: 30 μg total protein was separated by SDS-polyacrylamide gels and transferred to PVDF transfer membrane and the membranes were incubated with specific antibodies for IRF8 (ab28696, Abcam), AR (ab74272, Abcam), p-STAT1(Tyr701), p-STAT1 (Ser727), STAT1 (Cell Signaling Technology), β-actin (bsm-33036M, Bioss, China).

Techniques: Transfection, Plasmid Preparation, Incubation, Expressing, Confocal Microscopy, Co-Immunoprecipitation Assay, Western Blot

(A) Knockdown efficiency in LNCaP-shIRF8 cells determined by western blot. (B) Absorbance at 450 nm of LNCaP-shIRF8 cultured with 5% FBS (left panel), 5% CSS (middle panel), or 5% CSS containing 1 nM R1881 (right panel) in 96-well plates for 24–120 h. (C) Representative images of clone formation of LNCaP-shNC and LNCaP-shIRF8 cells cultured for 10 days. (D) Representative sphere formation of LNCaP-shNC and LNCaP-shIRF8 cells cultured for 14 days. (E, F) Knockdown of IRF8 in tumorigenesis. Tumour growth of LNCaP-shIRF8 cells in BALB/c nude mice (E, n=9), and in castrated BALB/c nude mice (F, n=9). (G) Representative images of IHC staining of PCNA in LNCaP-shIRF8 BALB/c xenografts. Scale bar, 100 μm. (H, I) OE of IRF8 in tumorigenesis. Proliferation (H) of 22RV1-IRF8 overexpression cells in vitro and tumour growth of 22RV1-IRF8 overexpression cells in vivo (I, n=9). (J) Western blot analysis for p-P38 MAPK, P38 MAPK, p-ERK, ERK, p-AKT(Thr308), p-AKT(Ser473), AKT, CD133, Oct3/4, and β-actin in LNCaP-shNC and LNCaP-shIRF8 cells.

Journal: Cancer research

Article Title: Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance

doi: 10.1158/0008-5472.CAN-19-2549

Figure Lengend Snippet: (A) Knockdown efficiency in LNCaP-shIRF8 cells determined by western blot. (B) Absorbance at 450 nm of LNCaP-shIRF8 cultured with 5% FBS (left panel), 5% CSS (middle panel), or 5% CSS containing 1 nM R1881 (right panel) in 96-well plates for 24–120 h. (C) Representative images of clone formation of LNCaP-shNC and LNCaP-shIRF8 cells cultured for 10 days. (D) Representative sphere formation of LNCaP-shNC and LNCaP-shIRF8 cells cultured for 14 days. (E, F) Knockdown of IRF8 in tumorigenesis. Tumour growth of LNCaP-shIRF8 cells in BALB/c nude mice (E, n=9), and in castrated BALB/c nude mice (F, n=9). (G) Representative images of IHC staining of PCNA in LNCaP-shIRF8 BALB/c xenografts. Scale bar, 100 μm. (H, I) OE of IRF8 in tumorigenesis. Proliferation (H) of 22RV1-IRF8 overexpression cells in vitro and tumour growth of 22RV1-IRF8 overexpression cells in vivo (I, n=9). (J) Western blot analysis for p-P38 MAPK, P38 MAPK, p-ERK, ERK, p-AKT(Thr308), p-AKT(Ser473), AKT, CD133, Oct3/4, and β-actin in LNCaP-shNC and LNCaP-shIRF8 cells.

Article Snippet: 30 μg total protein was separated by SDS-polyacrylamide gels and transferred to PVDF transfer membrane and the membranes were incubated with specific antibodies for IRF8 (ab28696, Abcam), AR (ab74272, Abcam), p-STAT1(Tyr701), p-STAT1 (Ser727), STAT1 (Cell Signaling Technology), β-actin (bsm-33036M, Bioss, China).

Techniques: Western Blot, Cell Culture, Immunohistochemistry, Over Expression, In Vitro, In Vivo

(A) Western blot analysis for IRF8 and AR in the LNCaP-shIRF8 stable cell line for whole cell lysate (WCL), cytoplasm protein(Cyto), and nuclear protein(Nuc), β-actin, GAPDH, and lamin B were used as reference proteins, respectively. (B) Western blot analysis for IRF8 and AR in lysates of LNCaP cells or IRF8 and AR (AR full-length: ARfl and AR variants: ARvs) in 22RV1 cells 48 h after transfection with IRF8 plasmid (pIRF8) at various amounts (0.125–1 μg). (C) Western blot analysis of IRF8 and AR in HEK293T cells co-transfected with AR plasmid (0.3 μg) and different concentrations of IRF8 plasmid (0.125–1 μg) for 24 h and 48 h. (D) Western blot analysis of exogenous IRF8 and AR in PC3 cells transfected with AR plasmid (0.3 μg) and IRF8 plasmid (1 μg) alone or in combination for 48 h. (E) Western blot analysis of AR dimers under native polyacrylamide gel electrophoresis conditions in HEK293T cells transfected with pAR, pIRF8 and pFlag-Ub vector alone or in combination. (F) Western blot analysis of PSA, AR and IRF8 in LNCaP cells transfected with siRNA targeting IRF8 for 24 h. (G) Luciferase reporter assays for AR activity in IRF8-KD (LNCaP-shIRF8; left panels) and IRF8-OE (LNCaP-IRF8; right panels) LNCaP cells treated with DHT. ***p < 0.001 by one-way ANOVA.

Journal: Cancer research

Article Title: Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance

doi: 10.1158/0008-5472.CAN-19-2549

Figure Lengend Snippet: (A) Western blot analysis for IRF8 and AR in the LNCaP-shIRF8 stable cell line for whole cell lysate (WCL), cytoplasm protein(Cyto), and nuclear protein(Nuc), β-actin, GAPDH, and lamin B were used as reference proteins, respectively. (B) Western blot analysis for IRF8 and AR in lysates of LNCaP cells or IRF8 and AR (AR full-length: ARfl and AR variants: ARvs) in 22RV1 cells 48 h after transfection with IRF8 plasmid (pIRF8) at various amounts (0.125–1 μg). (C) Western blot analysis of IRF8 and AR in HEK293T cells co-transfected with AR plasmid (0.3 μg) and different concentrations of IRF8 plasmid (0.125–1 μg) for 24 h and 48 h. (D) Western blot analysis of exogenous IRF8 and AR in PC3 cells transfected with AR plasmid (0.3 μg) and IRF8 plasmid (1 μg) alone or in combination for 48 h. (E) Western blot analysis of AR dimers under native polyacrylamide gel electrophoresis conditions in HEK293T cells transfected with pAR, pIRF8 and pFlag-Ub vector alone or in combination. (F) Western blot analysis of PSA, AR and IRF8 in LNCaP cells transfected with siRNA targeting IRF8 for 24 h. (G) Luciferase reporter assays for AR activity in IRF8-KD (LNCaP-shIRF8; left panels) and IRF8-OE (LNCaP-IRF8; right panels) LNCaP cells treated with DHT. ***p < 0.001 by one-way ANOVA.

Article Snippet: 30 μg total protein was separated by SDS-polyacrylamide gels and transferred to PVDF transfer membrane and the membranes were incubated with specific antibodies for IRF8 (ab28696, Abcam), AR (ab74272, Abcam), p-STAT1(Tyr701), p-STAT1 (Ser727), STAT1 (Cell Signaling Technology), β-actin (bsm-33036M, Bioss, China).

Techniques: Western Blot, Stable Transfection, Transfection, Plasmid Preparation, Polyacrylamide Gel Electrophoresis, Luciferase, Activity Assay